185
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Immunological and hemostasiological disorders in women with ovarian hyperstimulation syndrome

, , &

References

  • Ando H, Furugori K, Shibata D, et al. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod 2003;18:1219–22
  • Delbaere A, Smits G, Olatunbosun O, et al. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum Reprod 2004;19:486–9
  • Abramov Y, Schenker JG, Lewin A, et al. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 1996;11:1381–6
  • Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 2010;27:121–8
  • Pellicer A, Albert C, Mercader A, et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1b, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999;71:482–9
  • Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997;3:255–66
  • Ajonuma LC. Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)? Med Hypotheses 2008;70:1174–8
  • Sukhikh HT, Saroyan TT, Korneev IE. Immune aspects of the pathophysiology of ovarian hyperstimulation syndrome. Obstetr Gynecol 2009;3:3–7
  • Korneeva IE, Ivanova AV, Barkalina NV. Ovarian hyperstimulation syndrome: prevention, diagnosis and treatment (review). Probl Reprod 2004;10:43–50
  • Golan A, Ron-el R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430–40
  • Mathur RS, Akande VA, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901–7
  • Villasante A, Pacheco A, Pau E, et al. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod 2008;23:662–7
  • Kasum M. New insights in mechanisms for development of ovarian hyperstimulation syndrome. Coll Antropol 2010;34:1139–43
  • Lamazou F, Legouez A, Letouzey V, et al. Ovarian hyperstimulation syndrome: pathophysiology, risk factors, prevention, diagnosis and treatment. J Gynecol Obstet Biol Reprod (Paris) 2011;40:593–611
  • Mahajan N. Ovarian hyperstimulation syndrome. Int J Infertil Fetal Med 2013;4:71–8
  • Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 2010;27:121–8
  • Chin-Der Chen, Hsin-Fu Chen, Hsin-Fen Lu, et al. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:1037–42
  • Levin I, Gamzu R, Pauzner D, et al. Elevated levels of CRP in ovarian hyperstimulation syndrome: an unrecognised potential hazard? BJOG 2005;112:952–5
  • Manolopoulos K, Lang U, Gips H, Braems GA. Elevated interleukin-10 and sex steroid levels in peritoneal fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 2001;99:226–31
  • Enskog A, Nilsson L, Brännström M. Low peripheral blood levels of the immunosuppressive cytokine interleukin 10 (IL-10) at the start of gonadotrophin stimulation indicates increased risk for development of ovarian hyperstimulation syndrome (OHSS). J Reprod Immunol 2001;49:71–85
  • Chen CD, Chen HF, Lu HF, et al. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:1037–42
  • Kumar P, Shen Q, Pivetti CD, et al. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med 2009;30:11–15
  • Rogolino A, Coccia ME, Fedi S, et al. Hypercoagulability, high tissue factor and low tissue factor pathway inhibit or levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood Coagul Fibrinolysis 2003;14:277–82

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.